Multiple Sclerosis KOL Insight Interview
We performed a 5-question survey of 20 ophthalmologists who treat retinal diseases to gauge current usage and projected future usage of agents for the treatment of wet and dry age-related macular degeneration (AMD) and diabetic macular edema (DME).
We conducted a survey of 20 infectious diseases specialists to evaluate current drug usage for the treatment of selected severe/inpatient infections and gauge physician interest in new drugs.
This survey of US primary care physicians (n=10) and endocrinologists (n=10) was undertaken to evaluate the impact of GLP-1 agonists if they were to be introduced in the Diabetes market.
We surveyed primary care physicians (n=10) and endocrinologists (n=10) to see how SGLT-2 inhibitors and the combo pills will be used and what the potential impact of usage with GLP-1 agonists may have.
Crenezumab data was negative in a Phase II study in mild to moderate AD. The signal in not pre-specified isn’t convincing. These data likely will have ethical implications for the asymptomatic, genetic AD predisposition study in the Columbian trial.
Discusses percent not meeting goal and projected usage of PCSK9 and CETP inhibitors in various scenarios based on outcomes data.
Discusses usage of PCSK9 and CETP inhibitors in various scenarios based on outcomes data
Zontivity was approved (May 8, 2014) for use with clopidogrel/aspirin, its label was relatively benign, not reporting bleeding in the overall trial, which included stroke/TIA patients who had excessive bleeding with the drug, or in ACS trial, where there was also excessive bleeding.
Physicians are starting to use Perjeta (Roche) as an add-on to Herceptin in the adjuvant setting due to a recent change in NCCN (National Comprehensive Cancer Network, an alliance of major cancer centers) guidelines.
Diagnostics/diagnostic techniques discussed:
etarfolatide/folic acid, BRCA mutation testing
The European Association for the Study of the Liver (EASL) held the 2014 International Liver Meeting in London from April 9-13. The main focus of this year’s meeting was the clinical use of currently approved and soon-to-be approved, direct-acting antivirals for Hepatitis C.
Drugs and drug candidates discussed:
palbociclib, neratinib, Herceptin, Perjeta, Kadcyla, Tykerb, Afinitor
The study was just closed early, as LCZ696 increased time to first occurrence of either
cardiovascular death or heart failure hospitalization, though details have not been released.
We surveyed 10 US Cardiologists to get a preview of how they would use LCZ696 under different
assumptions about what the study found.
These pathways can be targeted either at the cell surface receptor
level or their downstream signaling cascades. Currently, everolimus in combination with
exemestane represents a new standard of care for patients progressing on non-steroidal AIs.
HDAC inhibitors have also shown promising results For innate resistance, the combination of
fulvestrant and AI in the front line setting represents a new treatment option, particularly for
patients who present with de novo metastatic disease.
Eslicarbazepine has been approved in ex-US markets including the EU for years.
We surveyed 10 US Neurologists to determine prelaunch perceptions of Aptiom.
KOL Highlights Include: The prevalence of cirrhosis due to NASH will far exceed that of cirrhosis due to Hepatitis C. Decreases in NAS score due to liver fat changes are not predictive of beneficial outcomes. Increasing LDL in patients with fatty liver disease is a concern. Results seen in animal models of NAFLD/NASH translate to […]
Macitentan is a novel dual endothelin receptor antagonist (ERA)
showing sustained receptor occupancy
The prevalence data would suggest that in the US population about 30% of our population has fatty liver or NAFLD and of those 25% may have NASH and of those patients with NASH 25% percent may have fibrosis and progress to cirrhosis. It’s almost a pyramid effect, there may be 80 million Americans walking around with NAFLD, but to climb up to the top of the pyramid and develop cirrhosis would be about 5% of that total population, but that’s still significant because that would mean that the prevalence of cirrhosis [due to NASH] will exceed that of hepatitis C-related cirrhosis ten-fold
Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer
Areas covered: Selexipag is rapidly hydrolyzed to an active metabolite, ACT-333679. Both selexipag and its metabolite are highly selective for the IP receptor compared with other prostanoid receptors. This selectivity for the IP receptor offers the potential for improved tolerability with selexipag, as side effects (e.g., nausea and vomiting) that might result from activation of the other prostanoid receptors may be minimized.
At SfN, they showed some interesting preclinical data on the affect on the 5-HT7 and how it works in some animal models of cognition…especially those injected with PCPA. And you know in depression, they also did what we call the chronic mild stress (CMS)
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!